bioAffinity Technologies Inc (BIAF) 시세

BIAF...8467...🥳...Moving up slowly off my 7099 Alert...10 Million range Float...

georgie18

Member Level
Re: georgie18 post# 672639

Tuesday, January 28, 2025 7:23:15 PM

Post#
672665
of 672673
BIAF...825...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 158

Tuesday, January 28, 2025 3:15:10 PM

Post#
159
of 159
BIAF...8026...🥳...Creeping up slowly...Off my .7099 Alert...

georgie18

Member Level
Re: georgie18 post# 672585

Tuesday, January 28, 2025 2:17:36 PM

Post#
672625
of 672638
BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

BIAF...825...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 158

Tuesday, January 28, 2025 3:15:10 PM

Post#
159
of 159
BIAF...8026...🥳...Creeping up slowly...Off my .7099 Alert...

georgie18

Member Level
Re: georgie18 post# 672585

Tuesday, January 28, 2025 2:17:36 PM

Post#
672625
of 672638
BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

BIAF...8026...🥳...Creeping up slowly...Off my .7099 Alert...

georgie18

Member Level
Re: georgie18 post# 672585

Tuesday, January 28, 2025 2:17:36 PM

Post#
672625
of 672638
BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

BIAF.............................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

BIAF.......................................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

BIAF under $2

BIAF.................................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

BIAF under $3

It does at that

Bought some this morning...looks good

BIAF.............................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

BIAF under $3

BIAF.............................................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

BIAF new 52 week high

BIAF under $2

BIAF under $2

Share count has only gone from 8.3M-8.5M since 2022. Not much warrant activity to work through either. Very surprised to see dilution has been minimal here. One would think this would get a pop soon...

Earnings supposedly on 5/15/23. Wondering how that $11.8M cash on hand is holding up.

Does seem like it could be building up to something. I guess time will tell.

Slowly gaining price ground.

Waiting patiently for an update on their trials.

MM's just took out some stop losses. NEVER use them on a company with this much potential!

She's starting to run on NITRO.

$2.65 - $2.75 looks to be support. One piece of decent news and this sweetheart will be above $5 in short order.

Picked up a bunch of shares under $2.50 earlier. This company has POTENTIAL!

$2.50ish looks to be the bottom. (Right now, anyway).

BIAF: An Astronaut buddy of mine --- on duty, up in the International Space Station --- just texted me a live film-clip of BIAF zooming by him, on its way to Planet JUPITER just now!! (See below.)

BIAF: See my latest DDAmanda 'CHART', just now, for (BIAF)!!!

BIAF: Hey, King EZ, I had to WAIT until it settled-down, but jumped-on some. Their (Medical) news today looks damn important for perhaps a long-term run here. GOOD LUCK!!
https://www.businesswire.com/news/home/20230124005372/en/bioAffinity-Technologies-Announces-Publication-of-Results-of-Clinical-Trial-in-Peer-Reviewed-Journal-Respiratory-Research

$BIAF: Beat me by a minute........ WOooooooooooohhoooooooooooo


Now $2.30

Ohhhhhhhh yaaaaaaaaaaaaaa............. I see it


Also BIAFW


GO $BIAF

Can it stay over $2
Nice news .. Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity

bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.

CyPath® Lung showed 92% sensitivity and 87% specificity in high-risk patients who had nodules smaller than 20 millimeters or no nodules in the lung, with an area under the ROC curve of 94%. Overall, the test resulted in specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer. More than half of those in the cancer cohort had early Stage I or II lung cancer. CyPath® Lung detected multiple forms of cancer including adenocarcinoma, squamous cell carcinoma and small cell lung cancer.

“The fact that CyPath® Lung can accurately predict lung cancer at an early stage in patients with small nodules is particularly important. Findings of lesions between six and 20 millimeters as a result of lung cancer screening can lead to unnecessary invasive procedures or a ‘watchful waiting’ period for patients,” said Vivienne Rebel, MD, PhD, bioAffinity Chief Medical and Science Officer and Executive Vice President. “Our test is intended for use with patients who display these indeterminant nodules to increase the accuracy of lung cancer screening and provide certainty for patients and their physicians.”

“CyPath® Lung uses an automated flow-based approach combined with machine learning that can be put into routine lab use without requiring expert evaluation of samples or being subject to operator bias,” said Madeleine Lemieux, PhD, who is first author and led development of the automated analysis used in CyPath® Lung. “The entire sample is rapidly analyzed which ensures maximal sensitivity. The automated, numerical analysis captures complex interactions between lung cancer and the micro-environment to reliably predict the presence of lung cancer that would not be possible for even expert individuals to do from visual flow data.”

Before working with bioAffinity Technologies, Dr. Lemieux was a computational biologist at the Dana Farber Institute and Harvard Medical School. She has contributed to more than 40 publications leveraging data from high-throughput platforms. Dr. Lemieux and Dr. Rebel began their successful collaboration during their doctoral studies.

CyPath® Lung uses flow cytometry, a method able to interrogate individual cells in a fraction of a second, and automated analysis to identify parameters in sputum that are indicative of cancer. Unlike genomic or other molecular markers used in liquid biopsies, bioAffinity’s CyPath® technology does not collect genetic material for evaluation. Instead, CyPath® Lung analyzes the lung micro-environment and identifies whole cell populations that indicate cancer is present in the lung.

Insiders here have lost their honey pot... the complete lack of movement has wreaked havoc on their cost to borrow income.

I see a pop coming here soon. They will once again loan out all their shares on said pop and collect interest.

Then most likely they will take that interest and buyback at much lower prices, once they have driven the price down to new lows.

Correct me if I'm wrong but I see nothing in any prospectus keeping pre-ipo shareholders from selling SOME of their non-restricted securities. Also some of their restricted holdings will soon be vested and able to be exercised.

Per the investment prospectus, not all of the 6 million previously issued shares are restricted. Some of the stock options are "currently exercisable or exercisable within 60 days"

the last IPO Prospectus after certification states:

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that person or entity in the table below, all shares subject to options and warrants were deemed outstanding if such securities are currently exercisable, or would vest based on service-based vesting conditions within 60 days of August 17, 2022. These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity.

https://sec.report/Document/0001493152-22-021392/

I mean I could be reading this wrong, but this would lead to me to expect to see more public market dilution adding to the float around October 16th-17th??? The number of OS shown by brokers is already incorrect.

From what I am reading I believe Dilution Tracker to be correct and the OS is now around 8.38 million shares, with insiders owning probably somewhere around 3 million of it.

I was not referring to the underwriters. Shorts are usually dealt with on a broker to broker and transfer agent basis. The underwriters just drive price action, exercise, and sell shares into the market. That is until their lockup period is up and then they are basically a shareholder like the rest of us, unless there is more issuance. I was mainly referring to the decrease in share availability not being reflected in the short interest. I did not screen shot shares available last week so I do no remember the exact number, but it was not 0.

Underwriter's can't lend out shares to short for 30 days after the IPO launch. This was an early Sept. baby.

Does your broker show shares available to borrow?

I am seeing zero share available but only a 0.62% short interest on my broker.
Fintel also showing zero shares available but only 0.20% short interest.

Im no genius but this doesn't add up...

They also just dropped the share price below the bid several times today, without filling a single share. So when does the order book/lvl 2 actually start to matter?

On watch now. Retracing to double bottom coming.

Finally had it's first consecutive green days!

Will it keep it up?

Need to break and hold above this 4.05 - 4.20 range.

Well said

It can always go down. Insider ownership here gettin rich off loaning out shares for interest. With the way this trades I wouldn't doubt there's more shares owned than are actually in the float. The volume here just doesn't make sense. They will be able to continue to paint the books until all warrants are exercised and there's no ability to fudge the numbers anymore. That may never happen...

I agree that the news was pretty much moot. I bet it was just a fake pump to create some volume for short covering. Now, they will re-short it all over again... And sell exercised shares into the market to manipulate and create the down trend they want.

Like I keep saying.. Its trash underwriters... Go look at their history, they kill 90% of the companies they IPO. Their greed is beyond immense and the SEC won't shut it down just like they won't shut down PFOF. They don't care about a free market. They only care about a controllable market. There is no intention of protecting shareholders' interests.

I believe this will go up from here. Consolidation and selling is done. People started to realize that it can't go down anymore but it has huge potential to go up with any news.

The only way to make $$$$ in a shit market. Let them pump! :)

smart advice....

WOW what a jump on such seemingly moot news

I warned y'all on the 16th that they were going to pump soon. They will again if it retraces. They need to pump to get this pps up. Put it on your watchlist.

Trade the chart. When/if it retraces and consolidates in quiet mode, load for the next pr. This moves on news.

Complete fluff! All this tells us is what we already knew when the IPO happened. Just a rehash of old news!

wow, they bought higher than trading price. This says something big is coming.

News: BioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities.

Investors participating in bioAffinity Technologies’ financing exercised a total of 725,576 tradeable warrants at a price of $7.35 per share and 310,910 non-tradable warrants at a price of $7.656 per share. Combined with the Company's underwritten public offering of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant and one non-tradeable warrant, in which the Company announced the receipt of gross proceeds of approximately $7.9 million, the Company has received an aggregate of approximately $15.6 million as of September 28, 2022.

The Company intends to use the proceeds from the offering to expand existing operations and the commercialization of CyPath® Lung, a noninvasive test for the early detection of lung cancer which uses flow cytometry to count and characterize cells in a person’s sputum, or phlegm. The test’s automated analysis of the flow cytometry data detects cell populations that indicate cancer is present. CyPath® Lung has the potential to increase overall diagnostic accuracy of lung cancer diagnosis leading to increased survival while lowering the number of unnecessary invasive procedures, reducing patient anxiety, and lowering medical costs.

Proceeds may also be used in the Company’s pursuit of regulatory approvals and research and development of additional diagnostics, cancer therapeutics, and for working capital and general corporate purposes.